Result of AGM

N4 Pharma PLC

23 May 2024

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.

Resolution	For	For%	Against	Against%	Total	Witheld votes*
Ordinary Resolution 1 To receive the annual report and audited accounts for the year ended 31 December 2023	20,612,844	99.93%	13,980	0.07%	20,626,824	296,841
Ordinary Resolution 2 To re-elect Nigel Theobald as a Director of the Company	20,605,744	99.32%	141,080	0.68%	20,746,824	176,841
Ordinary Resolution 3 To re-elect David Templeton as a Director of the Company	20,605,744	99.32%	141,080	0.68%	20,746,824	176,841
Ordinary Resolution 4 To re-appoint Saffery Champness LLP as the Companyʼs auditor and to authorise the Directors to determine their remuneration	20,605,644	99.32%	140,980	0.68%	20,746,624	177,041
Ordinary Resolution 5 To authorise the Directors to allot shares	20,559,085	99.10%	187,539	0.90%	20,746,624	177,041
Special Resolution 6 To disapply pre-emption rights	20,506,310	99.00%	207,439	1.00%	20,713,749	209,916

*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

For more information please contact:

N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director	investors.n4pharma.com
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)	Tel: [phone]
InvestorHub Engage with us directly at N4 Pharma Investor Hub	Sign up at investors.n4pharma.com https://investors.n4pharma.com/link/Ky0AZe
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope	Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.

 

END